Switch to:
Synageva BioPharma Corp (NAS:GEVA)
Cash from Financing
$212.12 Mil (TTM As of Sep. 2014)

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2014, Synageva BioPharma Corp paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.79 Mil on other financial activities. In all, Synageva BioPharma Corp earned $0.79 Mil on financial activities for the three months ended in Sep. 2014.


Definition

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Synageva BioPharma Corp's Cash from Financing for the fiscal year that ended in Dec. 2013 is calculated as:

Cash from Financing(A: Dec. 2013 )
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred+Dividends+Other Financing
=281.193+0+0+0+5.159
=286.35

Synageva BioPharma Corp's Cash from Financing for the quarter that ended in Sep. 2014 is

Synageva BioPharma Corp Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2014 was 1.69 (Dec. 2013 ) + 204.088 (Mar. 2014 ) + 5.555 (Jun. 2014 ) + 0.789 (Sep. 2014 ) = $212.12 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

Cash from financing contains five items:

1. Net Issuance of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. If this number is positive, it means that the company has received more cash from issuing shares than it has paid to buy back shares. If this number is negative, it means that company has paid more cash to buy back shares than it has received for issuing shares.

Synageva BioPharma Corp's net issuance of stock for the three months ended in Sep. 2014 was $0.00 Mil. Synageva BioPharma Corp paid $0.00 Mil more to buy back shares than it received from issuing new shares.

2. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Synageva BioPharma Corp's net issuance of debt for the three months ended in Sep. 2014 was $0.00 Mil. Synageva BioPharma Corp received $0.00 Mil from issuing more debt.

3. Net Issuance of Preferred:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Synageva BioPharma Corp's net issuance of preferred for the three months ended in Sep. 2014 was $0.00 Mil. Synageva BioPharma Corp paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

4. Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Synageva BioPharma Corp's cash flow for dividends for the three months ended in Sep. 2014 was $0.00 Mil. Synageva BioPharma Corp received $0.00 Mil from paying cash dividends to shareholders.

5. Other Financing:
Money spent or earned by company from other financial activities.

Synageva BioPharma Corp's other financing for the three months ended in Sep. 2014 was $0.79 Mil. Synageva BioPharma Corp received $0.79 Mil on other financial activities.


Related Terms

Cash Flow from Operations, Cash Flow from Investing, Net Issuance of Stock, Net Issuance of Debt, Dividends, Net Issuance of Preferred


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Synageva BioPharma Corp Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Net Issuance of Stock 0.690.620.470.170.000.000.000.00192.74281.19
Net Issuance of Debt -0.270.000.000.000.000.000.0012.500.000.00
Net Issuance of Preferred 0.000.000.000.000.000.000.000.000.000.00
Dividends 0.000.000.000.00-55.470.000.000.000.000.00
Other Financing 0.000.000.000.000.000.000.000.191.365.16
Cash from Financing 0.410.620.470.17-55.470.000.0012.69194.10286.35

Synageva BioPharma Corp Quarterly Data

Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14Sep14
Net Issuance of Stock 0.00108.140.00111.060.19170.14-0.19200.930.000.00
Net Issuance of Debt 0.000.000.000.000.000.000.000.000.000.00
Net Issuance of Preferred 0.000.000.000.000.000.000.000.000.000.00
Dividends 0.000.000.000.000.000.000.000.000.000.00
Other Financing 0.170.470.432.030.400.851.883.165.560.79
Cash from Financing 0.17108.610.43113.090.59170.991.69204.095.560.79
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK